Alnylam Pharmaceuticals Stock Today
| ALNY Stock | USD 273.15 1.31 0.48% |
Performance15 of 100
| Odds Of DistressLess than 11
|
Alnylam Pharmaceuticals is trading at 273.15 as of the 18th of September 2024; that is 0.48 percent decrease since the beginning of the trading day. The stock's open price was 274.46. Alnylam Pharmaceuticals has less than a 11 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. Note, on November 16, 2018, Representative Josh Gottheimer of US Congress acquired under $15k worth of Alnylam Pharmaceuticals's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of May 2004 | Category Healthcare | Classification Health Care |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. The company has 128.38 M outstanding shares of which 3.77 M shares are presently shorted by private and institutional investors with about 3.64 trading days to cover. More on Alnylam Pharmaceuticals
Moving against Alnylam Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Alnylam Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO Director | MBChB MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsAlnylam Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Alnylam Pharmaceuticals' financial leverage. It provides some insight into what part of Alnylam Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Alnylam Pharmaceuticals (ALNY) is traded on NASDAQ Exchange in USA. It is located in 675 West Kendall Street, Cambridge, MA, United States, 02142 and employs 2,100 people. Alnylam Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 35.07 B. Alnylam Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 128.38 M outstanding shares of which 3.77 M shares are presently shorted by private and institutional investors with about 3.64 trading days to cover.
Alnylam Pharmaceuticals currently holds about 2.27 B in cash with 104.16 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.41.
Check Alnylam Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe majority of Alnylam Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Alnylam Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Alnylam Pharmaceuticals. Please pay attention to any change in the institutional holdings of Alnylam Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that on November 16, 2018, Representative Josh Gottheimer of US Congress acquired under $15k worth of Alnylam Pharmaceuticals's common stock.
Check Alnylam Ownership Details
Alnylam Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| T. Rowe Price Investment Management,inc. | 2024-06-30 | 3.2 M | |
| Norges Bank | 2024-06-30 | 2.3 M | |
| Geode Capital Management, Llc | 2024-06-30 | 2.1 M | |
| Jpmorgan Chase & Co | 2024-06-30 | 1.8 M | |
| American Century Companies Inc | 2024-06-30 | 1.4 M | |
| Legal & General Group Plc | 2024-06-30 | 926.3 K | |
| Bellevue Group Ag | 2024-06-30 | 919.8 K | |
| Ubs Asset Mgmt Americas Inc | 2024-06-30 | 835.4 K | |
| Northern Trust Corp | 2024-06-30 | 780.8 K | |
| Capital World Investors | 2024-06-30 | 15 M | |
| Vanguard Group Inc | 2024-06-30 | 12.5 M |
Alnylam Pharmaceuticals Historical Income Statement
Alnylam Stock Against Markets
Alnylam Pharmaceuticals Corporate Management
| Saraswathy Nochur | Equity Diversity | Profile | |
| Indrani JD | Executive Secretary | Profile | |
| Evan Lippman | Chief Officer | Profile | |
| Piyush JD | Chief Officer | Profile | |
| Alfred Boyle | Chief Officer | Profile | |
| Timothy Maines | Chief Officer | Profile |
Already Invested in Alnylam Pharmaceuticals?
The danger of trading Alnylam Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alnylam Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alnylam Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alnylam Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.